Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN)

Price 10,622.00p on 27-01-2023 at 18:30:19
Change -22.00p -0.21%
Buy 10,612.00p
Sell 10,608.00p
Buy / Sell AZN Shares
Last Trade: Unknown 2,467.00 at 10,600.00p
Day's Volume: 1,234,773
Last Close: 10,622.00p
Open: 10,668.00p
ISIN: GB0009895292
Day's Range 10,558.00p - 10,700.00p
52wk Range: 8,214.00p - 11,886.00p
Market Capitalisation: £164,620m
VWAP: 10,615.10212p
Shares in Issue: 1,550m

Recent Trades History Astrazeneca (AZN)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 2,467 10,600.00p Ordinary
Currency Conversion
OTC Trade
18:30:12 - 27-Jan-23
Unknown* 1,929 10,588.934p Ordinary
Currency Conversion
OTC Trade
18:08:53 - 27-Jan-23
Unknown* 19 10,620.00p Ordinary
Currency Conversion
OTC Trade
18:02:26 - 27-Jan-23
Unknown* 60 10,602.62808p Ordinary
Currency Conversion
OTC Trade
18:01:58 - 27-Jan-23
Unknown* 2,678 10,622.00p Ordinary
Currency Conversion
OTC Trade
17:56:07 - 27-Jan-23
Unknown* 48 10,593.833p Ordinary
Currency Conversion
OTC Trade
17:53:50 - 27-Jan-23
Unknown* 5 10,613.00p Ordinary
Currency Conversion
OTC Trade
17:53:50 - 27-Jan-23
Unknown* 29 10,594.00p Ordinary
Currency Conversion
OTC Trade
17:53:50 - 27-Jan-23
Unknown* 94 10,594.085p Ordinary
Currency Conversion
OTC Trade
17:53:49 - 27-Jan-23
Unknown* 10 10,614.21373p Ordinary
Currency Conversion
OTC Trade
17:47:53 - 27-Jan-23

Share Price History for Astrazeneca

Time period:
to
Date Open High Low Close Volume

Share News for Astrazeneca

IN BRIEF: AstraZeneca loses emergency use authorisation for Evusheld

26th Jan 2023 21:30

AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Reports that the US Food & Drug Administration withdrew its authorisation for the emergency use of Evusheld, a medicine used to prevent Covid-19 in adults and adolescents, for the emergency use for pre-exposure prophylaxis of Covid-19 in the US. Says that the FDA will make a determination about reinstating authorisation of Evusheld if the national prevalence of resistant variants decreases to 90%. Explains that the withdrawal is due the sustained high frequency of circulating SARS-CoV-2 variants that Evusheld does not retain in vitro neutralisation against. Read More

TOP NEWS: AstraZeneca's Enhertu approved in EU for breast cancer form

26th Jan 2023 09:40

(Alliance News) - AstraZeneca PLC on Thursday said its cancer drug Enhertu, which it develops with Daiichi Sankyo Co Ltd, has been approved in the EU for the treatment of metastatic breast cancer. Read More

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

25th Jan 2023 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning: Read More

LONDON MARKET OPEN: FTSE 100 lags as other indices make headway

24th Jan 2023 09:33

(Correcting December borrowing figure to billion.) Read More

LONDON MARKET OPEN: FTSE 100 lags as other indices make headway

24th Jan 2023 09:14

(Alliance News) - Stock prices in London opened mixed on Tuesday, with the FTSE 100 underperforming, as a more positive mood prevailed elsewhere. Read More

FTSE 100 Latest
Value7,765.15
Change4.04

Login to your account

Forgot Password?

Not Registered